FDA Approves Degevma Biosimilar for Multiple Bone-Related Cancer Indications

The U.S. Food and Drug Administration (FDA) has approved Degevma (denosumab-adet), a biosimilar to Xgeva (denosumab), for all its reference product's indications. This includes preventing bone complications in adults with advanced cancer that has spread to the bone, treating giant cell tumor of bone, and managing hypercalcemia of malignancy. This approval provides an additional treatment option for patients and marks Teva's second biosimilar for bone conditions this year, potentially increasing access and affordability.